Memphasys raises $0.84 million, cuts operating costs
A capital raise of $0.84 million (before costs) demonstrates growing confidence in the Felix sperm separation device, according to ASX-listed reproductive biotechnology company Memphasys. According to a statement from the company on Monday, it has successfully completed a share placement for that amount, with an additional non-renounceable rights issue to eligible shareholders potentially raising up…